10-K: Nevro Corp. Navigates Merger Amidst Market Challenges: 2024 10-K Report Highlights

Nevro Corp.'s 2024 10-K filing reveals a pending merger with Globus Medical, alongside financial results impacted by market headwinds and strategic shifts.

Summary

• Nevro Corp. is set to merge with Globus Medical in a deal valued at approximately $250 million, expected to close in the second quarter of 2025.
• The company focuses on chronic pain solutions, including spinal cord stimulation (SCS) and sacroiliac (SI) joint fusion devices.
• Nevro's HFX SCS platform, featuring 10 kHz Therapy, has shown superiority in treating back and leg pain compared to traditional SCS.
• In November 2023, Nevro acquired Vyrsa Technologies to expand its portfolio in the SI joint fusion market.
• The 2023 global market for SCS therapy was estimated at $2.4 billion, but experienced relatively flat growth due to alternative minimally invasive spine procedures.
• Total revenue for 2024 was $408.5 million, a decrease from $425.2 million in 2023.
• The company reported a net loss of $113.4 million for 2024, compared to a net loss of $92.2 million in 2023.
• Nevro is improving manufacturing efficiency at its Costa Rica facility to lower per-unit costs.
• The company is investing in research and development to expand the use of 10 kHz Therapy for other chronic pain indications.
• As of December 31, 2024, Nevro had 1,099 employees globally.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the merger provides a positive outlook, the financial results indicate challenges and the company faces significant competition and regulatory hurdles.

Positives

• The merger with Globus Medical provides a significant cash infusion and potential for growth.
• Nevro's 10 kHz Therapy has strong clinical evidence supporting its efficacy in treating chronic pain.
• The acquisition of Vyrsa Technologies diversifies Nevro's product portfolio and expands its market reach.
• The launch of HFX AdaptivAI demonstrates Nevro's commitment to innovation in pain management.
• The company is working to improve manufacturing efficiency and reduce per-unit costs.

Negatives

• Revenue decreased in 2024 compared to 2023, indicating challenges in the current market environment.
• The company reported a significant net loss for 2024, highlighting ongoing financial pressures.
• The SCS market is experiencing relatively flat growth due to alternative minimally invasive spine procedures.
• The company is dependent on continued market acceptance of its 10 kHz Therapy.
• The company is subject to risks associated with third-party manufacturers and suppliers.

Risks

• The merger with Globus Medical may not be completed or could be delayed.
• The company faces intense competition from larger, well-established medical device companies.
• Third-party payors may not provide adequate coverage and reimbursement for Nevro's products.
• The company may be involved in intellectual property disputes, which could be costly and time-consuming.
• Failure to maintain FDA approval or foreign approval or certification could prevent the company from selling its products.
• Unfavorable global economic conditions could negatively impact the company's business and financial performance.

Future Outlook

The company expects to continue investing in commercial infrastructure, research and development, and product enhancements. The merger with Globus Medical is expected to close in the second quarter of 2025.

Industry Context

The SCS market is experiencing relatively flat growth due to alternative minimally invasive spine procedures. Nevro is diversifying its product portfolio to address a wider range of patient needs and expand its market reach.

Comparison to Industry Standards

• Nevro competes with major players like Medtronic, Boston Scientific, and Abbott Laboratories, all of whom have greater capital resources and established market presence.
• Medtronic and Saluda Medical have launched closed-loop SCS devices, which aim to provide more responsive and personalized therapy.
• Abbott Laboratories received FDA approval for a SCS system that offers an alternate low frequency waveform called BurstDR.
• Medtronic gained FDA approval for the Intellis spinal cord stimulator and purchased Stimgenics, which includes a proprietary SCS waveform called Differential Target Multiplexed (DTM).
• Boston Scientific broadly launched the WaveWriter SCS system and its Fast Acting Sub-perception Therapy (FAST).
• Saluda received FDA approval of its low frequency closed loop system for the treatment of chronic pain in March 2022 and EU approval in September 2019.
• Biotronik is the newest entrant to the market with approval for SCS system, Prospera in March 2023.

Legal Proceedings

• The company is cooperating with a civil investigative demand (CID) from the United States Attorneys Office for the Northern District of California relating to the company's spinal cord stimulation system (SCS System).
• The CID primarily relates to marketing, promotion and billing practices, not the therapeutic or safety attributes of the Company's SCS System.

Stakeholder Impact

• Shareholders will receive $5.85 per share in cash upon completion of the merger.
• Employees face uncertainty regarding their future employment following the merger.
• Customers may benefit from the combined resources and expertise of Nevro and Globus Medical.
• Suppliers may be affected by changes in purchasing patterns following the merger.
• Creditors may be impacted by changes in the company's debt structure following the merger.

Next Steps

• Seek stockholder approval for the merger with Globus Medical.
• Obtain regulatory approvals for the merger.
• Continue commercialization efforts for Senza and HFX iQ.
• Invest in research and development to expand the use of 10 kHz Therapy for other chronic pain indications.
• Improve manufacturing efficiency at the Costa Rica facility.

Key Dates